Severe Measles in Immunocompromised Patients
Leonard J. Kaplan, MD, PhD;
Robert S. Daum, MD;
Mary Smaron, PhD;
Carol A. McCarthy, MD
JAMA. 1992;267(9):1237-1241.
Abstract
| |
Objectives.
—To describe the severity of measles in immunocompromised hosts and to assess preventive and therapeutic modalities.
Data Sources.
—Patients admitted to two academic medical centers between September 1989 and December 1990 and English language references obtained by MEDLINE from 1963 to 1991. Bibliographies were used to identify reports prior to 1963.
Study Selection.
—We identified nine immunocompromised patients with measles. Further analysis was based on 35 patients from two cohort studies of measles in oncology patients and 24 reported cases of measles in human immunodeficiency virus (HIV)—infected patients.
Data Extraction.
—Clinical data are presented from the nine patients we treated. Information concerning measles complications, presence of rash, use of prophylactic immunoglobulin, and therapeutic measures was extracted from the literature.
Data Synthesis.
—Of our nine patients, eight developed severe complications and two died. Two patients had no rash. In combining our patients with those from the literature, severe complications occurred in about 80%. The case fatality rate for severe measles was about 70% for oncology patients and about 40% for HIV-infected patients. Rash was absent in about 30%. The efficacy of prophylactic or therapeutic measures could not be assessed due to the small number of patients. However, we observed a rapid defervescence following administration of ribavirin. Vaccinated, HIV-infected patients had a lower mortality rate than those not previously vaccinated (P =.06).
Conclusions.
—Measles is a severe illness in immunocompromised patients, and the absence of rash is frequent. While treatment is supportive, ribavirin requires further study. Measles vaccine may be efficacious in HIV-infected patients. Vaccination of oncology patients should be reassessed.
(JAMA. 1992;267:1237-1241)
Author Affiliations
From the Departments of Medicine (Dr Kaplan) and Pediatrics (Drs Daum and McCarthy) and the Clinical Microbiology Laboratory (Dr Smaron), the University of Chicago (Ill) Hospitals.
Footnotes
Reprint requests to Section of Pediatric Infectious Diseases, University of Chicago/Wyler Children's Hospital, 5841 S Maryland Ave, MC 6054, Chicago, IL 60637-1470 (Dr McCarthy).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Measles in the United Kingdom: can we eradicate it by 2010?
Asaria and MacMahon
BMJ 2006;333:890-895.
FULL TEXT
Immune Containment and Consequences of Measles Virus Infection in Healthy and Immunocompromised Individuals
Permar et al.
CVI 2006;13:437-443.
FULL TEXT
Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles
Pan et al.
Proc. Natl. Acad. Sci. USA 2005;102:11581-11588.
ABSTRACT
| FULL TEXT
Role of CD8+ Lymphocytes in Control and Clearance of Measles Virus Infection of Rhesus Monkeys
Permar et al.
J. Virol. 2003;77:4396-4400.
ABSTRACT
| FULL TEXT
Viral Pneumonias in Adults: Radiologic and Pathologic Findings
Kim et al.
RadioGraphics 2002;22:S137-149.
ABSTRACT
| FULL TEXT
Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence
Davies and Woo
Rheumatology (Oxford) 2002;41:937-941.
ABSTRACT
| FULL TEXT
Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil
Machado et al.
Blood 2002;99:83-87.
ABSTRACT
| FULL TEXT
Measles Immunization in HIV-Infected Children
Committee on Infectious Diseases and Committee on
Pediatrics 1999;103:1057-1060.
ABSTRACT
| FULL TEXT
Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host
Pirofski and Casadevall
Clin. Microbiol. Rev. 1998;11:1-26.
ABSTRACT
| FULL TEXT
Patterns of Infection After Pediatric Liver Transplantation
George et al.
Arch Pediatr Adolesc Med 1992;146:924-929.
ABSTRACT
|
